Biomarkers of renal disease and progression in patients with diabetes

Journal of Clinical Medicine

Volumn 4, Issue 5, 2015, Pages 1010-1024

  Hojs, Radovan ^a,b   Ekart, Robert ^a,b   Bevc, Sebastjan ^a,b   Hojs, Nina ^a,b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Biomarkers; Diabetes; Inflammation; Nephropathy; Oxidative stress; Tubular biomarkers

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; CREATININE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE KIDNEY FAILURE; ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); OXIDATIVE STRESS; PROGNOSIS; PROTEINURIA; REVIEW;

EID: 84977937774     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4051010     Document Type: Review

References (80)

1. Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.; Yang, C.W. Chronic kidney disease: Global dimension and perspectives. Lancet 2013, 382, 260–272.
2. Anand, S.; Bitton, A.; Gaziano, T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS ONE 2013, 8, e72860.
3. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am. J. Kidney Dis. 2007, 49, S12–S154.
4. MacIsaac, R.J.; Ekinci, E.I.; Jerums, G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am. J. Kidney Dis. 2014, 63, S39–S62.
5. Levey, A.S.; Coresh, J. Chronic kidney disease. Lancet 2012, 379, 165–180.
6. Perkins, B.A.; Ficociello, L.H.; Silva, K.H.; Finkelstein, D.M.; Warram, J.H.; Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2003, 348, 2285–2293.
7. Gilbert, R.E.; Cooper, M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 1999, 56, 1627–1637.
8. Mishra, J.; Dent, C.; Tarabishi, R.; Mitsnefes, M.M.; Ma, Q.; Kelly, C.; Ruff, S.M.; Zahedi, K.; Shao, M.; Bean, J.; et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365, 1231–1238.
9. Hirsch, R.; Dent, C.; Pfriem, H.; Allen, J.; Beekman, R.H.; Ma, Q.; Dastrala, S.; Bennett, M.; Mitsnefes, M.; Devarajan, P. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr. Nephrol. 2007, 22, 2089–2095.
10. Wheeler, D.S.; Devarajan, P.; Ma, Q.; Harmon, K.; Monaco, M.; Cvijanovich, N.; Wong, H.R. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit. Care Med. 2008, 36, 1297–1303.
11. Constantin, J.M.; Futier, E.; Perbet, S.; Roszyk, L.; Lautrette, A.; Gillart, T.; Guerin, R.; Jabaudon, M.; Souweine, B.; Bazin, J.E.; et al. Plasma neutrophil gelatinaseassociated lipocalin is an early marker of acute kidney injury in adult critically ill patients: A prospective study. J. Crit. Care 2010, 25, doi:10.1016/j.jcrc.2009.05.010.
12. Haase-Fielitz, A.; Bellomo, R.; Devarajan, P.; Story, D.; Matalanis, G.; Dragun, D.; Haase, M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study. Crit. Care Med. 2009, 37, 553–560.
13. Bolignano, D.; Coppolino, G.; Campo, S.; Aloisi, C.; Nicocia, G.; Frisina, N.; Buemi, M. Neutrophil gelatinase-associated lipocalin in patients with autosomal dominant polycystic kidney disease. Am. J. Nephrol. 2007, 27, 373–378.
14. Paragas, N.; Nickolas, T.L.; Wyatt, C.; Forster, C.S.; Sise, M.; Morgello, S.; Jagla, B.; Buchen, C.; Stella, P.; Sanna-Cherchi, S.; et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2009, 20, 1687–1692.
15. Bolignano, D.; Coppolino, G.; Lacquaniti, A.; Nicocia, G.; Buemi, M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press. Res. 2008, 31, 274–279.
16. Ding, H.; He, Y.; Li, K.; Yang, J.; Li, X.; Lu, R.; Gao, W. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol. 2007, 123, 227–234.
17. Bolignano, D.; Lacquaniti, A.; Coppolino, G.; Donato, V.; Campo, S.; Fazio, M.R.; Nicocia, G.; Buemi, M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 337–344.
18. Yang, Y.H.; He, X.J.; Chen, S.R.; Wang, L.; Li, E.M.; Xu, L.Y. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: One year observational follow-up study. Endocrine 2009, 36, 45–51.
19. Smith, E.R.; Lee, D.; Cai, M.M.; Tomlinson, L.A.; Ford, M.L.; McMahon, L.P.; Holt, S.G. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD). Nephrol. Dial. Transplant. 2013, 28, 1569–1579.
20. Nauta, F.L.; Boertien, W.E.; Bakker, S.J.; van Goor, H.; van Oeveren, W.; de Jong, P.E.; Bilo, H.; Gansevoort, R.T. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34, 975–981.
21. Nielsen, S.E.; Andersen, S.; Zdunek, D.; Hess, G.; Parving, H.H.; Rossing, P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011, 79, 1113–1118.
22. Chou, K.M.; Lee, C.C.; Chen, C.H.; Sun, C.Y. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS ONE 2013, 8, e54863.
23. Van Timmeren, M.M.; van den Heuvel, M.C.; Bailly, V.; Bakker, S.J.; van Goor, H.; Stegeman, C.A. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 2007, 212, 209–217.
24. Bonventre, J.V. Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. Nephrol. Dial. Transplant. 2009, 24, 3265–3268.
25. Han, W.K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J.V. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 2002, 62, 237–244.
26. Shao, X.; Tian, L.; Xu, W.; Zhang, Z.; Wang, C.; Qi, C.; Ni, Z.; Mou, S. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: A meta-analysis. PLoS ONE 2014, 9, e84131.
27. Ko, G.J.; Grigoryev, D.N.; Linfert, D.; Jang, H.R.; Watkins, T.; Cheadle, C.; Racusen, L.; Rabb, H. Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI to CKD transition. Am. J. Physiol. Renal Physiol. 2010, 298, F1472–F1483.
28. Van Timmeren, M.M.; Vaidya, V.S.; van Ree, R.M.; Oterdoom, L.H.; de Vries, A.P.; Gans, R.O.; van Goor, H.; Stegeman, C.A.; Bonventre, J.V.; Bakker, S.J. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 2007, 84, 1625–1630.
29. Conway, B.R.; Manoharan, D.; Manoharan, D.; Jenks, S.; Dear, J.W.; McLachlan, S.; Strachan, M.W.; Price, J.F. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int. 2012, 82, 812–818.
30. Kamijo-Ikemori, A.; Sugaya, T.; Kimura, K. Urinary fatty acid binding protein in renal disease. Clin. Chim. Acta 2006, 374, 1–7.
31. Kamijo-Ikemori, A.; Sugaya, T.; Obama, A.; Hiroi, J.; Miura, H.; Watanabe, M. Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am. J. Pathol. 2006, 169, 1107–1117.
32. McMahon, B.A.; Murray, P.T. Urinary liver fatty acid-binding protein: Another novel biomarker of acute kidney injury. Kidney Int. 2010, 77, 657–659.
33. Yokoyama, T.; Kamijo-Ikemori, A.; Sugaya, T.; Hoshino, S.; Yasuda, T.; Kimura, K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am. J. Pathol. 2009, 174, 2096–2106.
34. Kamijo, A.; Sugaya, T.; Hikawa, A.; Yamanouchi, M.; Hirata, Y.; Ishimitsu, T.; Numabe, A.; Takagi, M.; Hayakawa, H.; Tabei, F.; et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Celluar Biochem. 2006, 284, 175–182.
35. Nielsen, S.E.; Sugaya, T.; Hovind, P.; Baba, T.; Parving, H.H.; Rossing, P. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010, 33, 1320–1324.
36. Kamijo-Ikemori, A.; Sugaya, T.; Yasuda, T.; Kawata, T.; Ota, A.; Tatsunami, S.; Kaise, R.; Ishimitsu, T.; Tanaka, Y.; Kimura, K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011, 34, 691–696.
37. Parikh, C.R.; Lu, J.C.; Coca, S.G.; Devarajan, P. Tubular proteinuria in acute kidney injury: A critical evaluation of current status and future promise. Ann. Clin. Biochem. 2010, 47, 301–312.
38. Holdt-Lehmann, B.; Lehmann, A.; Korten, G.; Nagel, H.; Nizze, H.; Schuff-Werner, P. Diagnostic value of urinary alanine aminopeptidase and N-acetyl-beta-D-glucosaminidase in comparison to alpha 1-microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin. Chim. Acta 2000, 297, 93–102.
39. Vaidya, V.S.; Niewczas, M.A.; Ficociello, L.H.; Johnson, A.C.; Collings, F.B.; Warram, J.H.; Krolewski, A.S.; Bonventre, J.V. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int. 2011, 79, 464–470.
40. Kern, E.F.; Erhard, P.; Sun, W.; Genuth, S.; Weiss, M.F. Early urinary markers of diabetic kidney disease: A nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am. J. Kidney Dis. 2010, 55, 824–834.
41. Devarajan, P. The Use of Targeted Biomarkers for Chronic Kidney Disease. Adv. Chronic Kidney Dis. 2010, 17, 469–479.
42. Navarro-González, J.F.; Mora-Fernández, C.; Muros de Fuentes, M.; García-Pérez, J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 2011, 7, 327–340.
43. Elmarakby, A.A.; Sullivan, J.C. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 2012, 30, 49–59.
44. Hasegawa, G.; Nakano, K.; Sawada, M.; Uno, K.; Shibayama, Y.; Ienaga, K.; Kondo, M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991, 40, 1007–1012.
45. Hasegawa, G.; Nakano, K.; Kondo, M. Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 1995, 15, 1–4.
46. Pickup, J.C.; Mattock, M.B.; Chusney, G.D.; Burt, D. NIDDM as a disease of the innate immune system: Association of the acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40, 1286–1292.
47. Saraheimo, M.; Teppo, A.M.; Forsblom, C.; Fagerudd, J.; Groop, P.H. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003, 46, 1402–1407.
48. Tong, M.; Carrero, J.J.; Qureshi, A.R.; Anderstam, B.; Heimbürger, O.; Bárány, P.; Axelsson, J.; Alvestrand, A.; Stenvinkel, P.; Lindholm, B.; et al. Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2007, 2, 889–897.
49. Wolkow, P.P.; Niewczas, M.A.; Perkins, B.; Ficociello, L.H.; Lipinski, B.; Warram, J.H.; Krolewski, A.S. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J. Am. Soc. Nephrol. 2008, 19, 789–797.
50. Moriwaki, Y.; Yamamoto, T.; Shibutani, Y.; Aoki, E.; Tsutsumi, Z.; Takahashi, S.; Okamura, H.; Koga, M.; Fukuchi, M.; Hada, T. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metab. Clin. Exp. 2003, 52, 605–608.
51. Nakamura, A.; Shikata, K.; Hiramatsu, M.; Nakatou, T.; Kitamura, T.; Wada, J.; Itoshima, T.; Makino, H. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005, 28, 2890–2895.
52. Rivero, A.; Mora, C.; Muros, M.; García, J.; Herrera, H.; Navarro-González, J.F. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. (Lond.) 2009, 116, 479–492.
53. Navarro, J.F.; Milena, F.J.; Mora, C.; Leon, C.; Garcıa, J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol. 2006, 26, 562–570.
54. Navarro, J.F.; Milena, F.; Mora, C.; León, C.; Claverie, F.; Flores, C.; García, J. Tumor necrosis factor-α gene expression in diabetic nephropathy: Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. 2005, 68, S98–S102.
55. Navarro, J.F.; Mora, C.; Macıa, M.; Garcıa, J. Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am. J. Kidney Dis. 2003, 42, 53–61.
56. Navarro, J.F.; Mora, C.; Rivero, A.; Gallego, E.; Chahin, J.; Macía, M.; Méndez, M.L.; García, J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am. J. Kidney Dis. 1999, 33, 458–463.
57. Niewczas, M.A.; Ficociello, L.H.; Johnson, A.C.; Walker, W.; Rosolowsky, E.T.; Roshan, B.; Warram, J.H.; Krolewski, A.S. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 2009, 4, 62–70.
58. Niewczas, M.A.; Gohda, T.; Skupien, J.; Smiles, A.M.; Walker, W.H.; Rosetti, F.; Cullere, X.; Eckfeldt, J.H.; Doria, A.; Mayadas, T.N.; et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 2012, 23, 507–515.
59. Gohda, T.; Niewczas, M.A.; Ficociello, L.H.; Walker, W.H.; Skupien, J.; Rosetti, F.; Cullere, X.; Johnson, A.C.; Crabtree, G.; Smiles, A.M.; et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 2012, 23, 516–524.
60. Lopes-Virella, M.F.; Baker, N.L.; Hunt, K.J.; Cleary, P.A.; Klein, R.; Virella, G.; DCCT/EDIC Research Group. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013, 36, 2317–2323.
61. Staunton, D.E.; Marlin, S.D.; Stratowa, C.; Dustin, M.L.; Springer, T.A. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988, 52, 925–933.
62. Shikata, K.; Makino, H. Microinflammation in the pathogenesis of diabetic nephropathy. J. Diabetes Investig. 2013, 4, 142–149.
63. Clausen, P.; Jacobsen, P.; Rossing, K.; Jensen, J.S.; Parving, H.H.; Feldt-Rasmussen, B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet. Med. 2000, 17, 644–649.
64. Lin, J.; Glynn, R.J.; Rifai, N.; Manson, J.E.; Ridker, P.M.; Nathan, D.M.; Schaumberg, D.A. Inflammation and progressive nephropathy in type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2008, 31, 2338–2343.
65. Rubio-Guerra, A.F.; Vargas-Robles, H.; Lozano, J.J.; Escalante-Acosta, B. Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic hypertensive patients. Kidney Blood Press. Res. 2009, 32, 106–109.
66. Tipping, P.G.; Holdsworth, S.R. T cells in glomerulonephritis. Semin. Immunopathol. 2003, 24, 377–393.
67. Kluth, D.C.; Erwig, L.P.; Rees, A.J. Multiple facets of macrophages in renal injury. Kidney Int. 2004, 66, 542–557.
68. Chow, F.; Nikolic-Paterson, D.J.; Ozols, E.; Atkins, R.C.; Rollin, B.J.; Tesch, G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69, 73–80.
69. Wada, T.; Furuichi, K.; Sakai, N.; Iwata, Y.; Yoshimoto, K.; Shimizu, M.; Takeda, S.I.; Takasawa, K.; Yoshimura, M.; Kida, H.; et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000, 58, 1492–1499.
70. Tashiro, K.; Koyanagi, I.; Saitoh, A.; Shimizu, A.; Shike, T.; Ishiguro, C.; Koizumi, M.; Funabiki, K.; Horikoshi, S.; Shirato, I.; et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 2002, 16, 1–4.
71. Morii, T.; Fujita, H.; Narita, T.; Shimotomai, T.; Fujishima, H.; Yoshioka, N.; Imai, H.; Kakei, M.; Ito, S. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complicat. 2003, 17, 5–11.
72. Amann, R.; Tinzmann, R.; Angelkort, B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003, 26, 2421–2425.
73. Takebayashi, K.; Matsumoto, S.; Aso, Y.; Inukai, T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab. 2006, 91, 2214–2217.
74. Huang, A.; Yang, Y.M.; Feher, A.; Bagi, Z.; Kaley, G.; Sun, D. Exacerbation of endothelial dysfunction during the progression of diabetes: Role of oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R674–R6781.
75. Chang, C.M.; Hsieh, C.J.; Huang, J.C.; Huang, I.C. Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus. Acta Diabetol. 2012, 49, S171–S177.
76. Whaley-Connell, A.; Sowers, J.R. Oxidative stress in the cardiorenal metabolic syndrome. Curr. Hypertens. Rep. 2012, 14, 360–365.
77. Hinokio, Y.; Suzuki, S.; Hirai, M.; Suzuki, C.; Suzuki, M.; Toyota, T. Urinary excretion of 8-oxo-7,8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002, 45, s877–s882.
78. Serdar, M.; Sertoglu, E.; Uyanik, M.; Tapan, S.; Akin, K.; Bilgi, C.; Kurt, I. Comparison of 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy. Free Radic. Res. 2012, 46, 1291–1295.
79. Tonolo, G.; Cherchi, S. Tubulointerstitial disease in diabetic nephropathy. Int. J. Nephrol. Renovasc. Dis. 2014, 7,107–115.
80. Araki, S.; Haneda, M.; Koya, D.; Sugaya, T.; Isshiki, K.; Kume, S.; Kashiwagi, A.; Uzu, T.; Maegawa, H. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 2013, 36, 1248–1253.